OTHER INFORMATION
−Removed: On August 4, 2020, the Company entered into an Employee Severance Agreement (the “Severance Agreement”) with Don Kalkofen, the Company’s Chief Financial Officer.
−Removed: The Severance Agreement provides that if the Company terminates Mr.
−Removed: Kalkofen’s employment without "cause"
−Removed: Kalkofen terminates employment for "good reason"
−Removed: (each as defined in the Severance Agreement), Mr.
−Removed: Kalkofen will receive:
−Removed: (a) salary continuation for nine months (12 months in the case of a “change in control termination” (as defined in the Severance Agreement));
−Removed: (b) COBRA continuation for the salary continuation period (or an equivalent cash payment if required by law);
−Removed: (c) in the case of a change in control termination only , payment of an amount equal to one twelfth of Mr.
−Removed: Kalkofen’s then current target bonus per month for the number of months of the severance period;
−Removed: and (d) in the case of a change in control termination only, acceleration of the vesting (and exercisability, as relevant) of equity awards held by Mr.
−Removed: Kalkofen immediately prior to termination.
−Removed: Payments and benefits under the Severance Agreement are subject to the execution of an effective release.
EXHIBIT INDEX
22 unchanged sentences
PROTAGONIST THERAPEUTICS, INC.
−Removed: August 6, 2020
+Added: November 4, 2020
/s/ Dinesh V.
1 unchanged sentence
(Principal Executive Officer)
−Removed: August 6, 2020
+Added: November 4, 2020
/s/ Don Kalkofen
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.